Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Sponsor: ScandiBioTherapeutics AB
Collaborators: Koç University, Koç University Hospital, Göteborg University, Sahlgrenska University Hospital, Sweden, KTH Royal Institute of Technology, University of Helsinki, Helsinki University Central Hospital, Monitor CRO

Purpose

To establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-cacetylcysteine, L-carnitine tartrate, NR and serine. Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation wil stimulate three different pathways to enhance hepatic β-oxidation and this study’s hypothesis is that this will result in decreased amount of fat in the liver.

Study Design

Randomized double blind, placebo controlled, parallel assignment

Dose

Half dose for 2 weeks (taken just after dinner) and full dose for 8 weeks (two equal doses taken just after breakfast and dinner)

Length of Intervention

10 weeks

Intrinsic Capacity

Vitality

Status

Recruiting

Condition or Disease 

Non-alcoholic Fatty Liver Disease (NAFLD)

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Liver Health, ClinicalANAD StaffLiver Health, Clinical Studies